US-based biopharmaceutical company Mabwell Therapeutics has received approval from China's National Medical Products ...

Certain types of tumors make up the majority of that 20%, such as melanoma, non-small cell lung cancer, and certain ...

9MW2821, a novel Nectin-4 targeting ADC developed by Mabwell, is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. It's also the ...

9MW2821 是迈威生物自主研发的靶向 Nectin-4 ADC 创新药，是国内同靶点药物中首个开展临床研究的品种，也是全球首款在宫颈癌适应症进入 III 期临床 ...

默沙东正与辉瑞和安斯泰来合作，针对这一组合进行评估，将其作为尿路上皮癌多阶段广泛临床开发计划的一部分，其中包括两项针对肌层浸润性膀胱癌的3期临床试验正在进行中，即KEYNOTE-B15和KEYNOTE-905试验。

9MW2821, a novel Nectin-4 targeting ADC developed by Mabwell, is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. It’s also the first ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

Nectin-4ADC在多个适应症中快速推进临床。迈威生物的核心产品9MW2821是研发进度最快的国产Nectin-4ADC，在尿路上皮癌（UC）、宫颈癌（CC）中已经进入到3期注册性临床。此外，9MW2821在食管癌（EC ...

（以下内容从德邦证券《NECTIN-4 ADC临床进展迅速，多个产品积极拓展海外市场》研报附件原文摘录） 迈威生物(688062) 2024上半年业绩：2024H1公司营业收入1.16亿元，同比增长28.42%，主要系药品销售 ...

9MW2821 共已获批开展 3 项关键性注册临床研究。 9MW2821 是迈威生物自主研发的靶向 Nectin-4 ADC 创新药，是国内同靶点药物中首个开展临床研究的品种，针对多项适应症开展的临床研究入组受试者 ...

迈威生物（688062.SH），一家全产业链布局的创新型生物制药公司，宣布其向国家药品监督管理局（NMPA）药品审评中心（CDE）递交的关于"9MW2821 对比研究者选择的化疗治疗含铂化疗失败的复发或转移性宫颈癌的随机、开放、对照、多中心 III 期临床研究"方案已获同意，将启动 9MW2821 治疗含铂化疗失败的复发或转移性宫颈癌的 III 期临床研究。 9MW2821 是迈威生物自主研发的靶 ...